Obesity Management Market
Popularity of Obesity Management System is No Longer Lean and Slim. Take the Health Check of the Market with FMI
Obesity Management Market by Drug Type, Surgery Type, Distribution Channel & Region - Forecast 2022 - 2032
Obesity Management Market Outlook (2022-2032)
[324 Pages Report] The obesity management market is expected to grow with a CAGR of 5.1%, from USD 828.71 million in 2022 to USD 1362.80 million by 2032. Due to the steep rise in obesity prevalence over the last two decades, the obesity management market is expected to generate significant revenue in the future.
The major factors expected to drive the obesity management market are an increase in the obese population, an increase in the number of bariatric surgeries, an increase in the adoption of online weight loss and weight management programmes, an increase in disposable income in developing economies, sedentary lifestyle, and increased government initiatives to raise awareness among obese populations.
|
Attributes |
Details |
|
Obesity Management Market CAGR (2022-2032) |
5.1% |
|
Obesity Management Market Size (2022) |
USD 828.71 million |
|
Obesity Management Market Size (2032) |
USD 1362.80 million |
Let us know your requirement to get
100% FREE customization
The Pertinent Windows Of Opportunity For Market Participants In The Coming Decade
Obesity affects one in every three adults in North America. Obesity causes a slew of chronic diseases, many of which can be avoided with proper weight management. Obese patients should be treated for the initial stage of hypertension by losing weight through lifestyle changes, pharmacological treatment, and/or bariatric surgery, according to the AHA.
The NHS in the United Kingdom has suggested that weight loss programmes educate people about the dangers of obesity and assist obese people in losing weight. People are becoming more aware of their physical appearance.
Elements Curtailing Obesity Management Demand
The high cost of surgeries and drugs may be a barrier to obesity management. Weight loss surgery is not reimbursed favourably in developing countries. Because weight management is a time-consuming process, medical payers are hesitant to provide reimbursement.
Furthermore, concerns about the safety of obesity management drugs are cruising clinical trials, with only a few drugs reaching the market. Drug-induced cardiovascular disease or cancer can be caused by certain drug formulations. These incidents have the potential to result in drug recalls.
The FDA, for example, has requested that Eisai withdraw its weight-loss drug Belviq from the market after clinical trials revealed an increased incidence of cancer in users.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystThe Key Determinants Are Generating Buzz Of Obesity Management
Geriatric population growth in developed countries, primarily due to improved healthcare leading to increased life expectancy, is driving the obesity management market. This is because geriatric people are highly susceptible to gaining noticeable body fat while losing muscle mass and functioning ability. As a result, the geriatric population is a critical segment of the obesity management market in both the short and long term.
Aside from that, genetics and medication side effects are linked to obesity, which must be handled with the aid of obesity management programmes. This helps to fuel the obesity management market.
Comparative View Of Adjacent Obesity Management Market
Obesity Management Market:
|
Attributes |
Obesity Management Market |
|
CAGR (2022-2032) |
5.1% |
|
Market Value (2028) |
USD 1116.92 million |
|
Growth Factor |
An increasing number of bariatric surgeries are being performed. |
|
Opportunity |
Online weight loss and weight management programmes are becoming more popular. |
|
Key Trends |
Expanding government initiatives to raise awareness among obese people. |
Clinical Alarm Management Market:
|
Attributes |
Clinical Alarm Management Market |
|
CAGR (2022-2032) |
10.4% |
|
Market Value (2028) |
USD 5.96 Billion |
|
Growth Factor |
The rising demand for healthcare, as well as the growing patient population, has resulted in an increase in the frequency of patient alarms, regardless of priority. |
|
Opportunity |
With rising disease prevalence and a growing geriatric population, clinical alarms have the potential to reduce costs and facilitate better patient management, which is a key contributor to market growth. |
|
Key Trends |
Electronic health records are becoming more popular. |
Dietary Fibers Market:
|
Attributes |
Dietary Fibers Market |
|
CAGR (2022-2032) |
12.6% |
|
Market Value (2028) |
USD 13.84 Billion |
|
Growth Factor |
The growing elderly population worldwide, combined with increased consumption of fortified food products, has driven the dietary fibre market. |
|
Opportunity |
Growing health consciousness among consumers worldwide, as well as sensitivity to nutrient-rich products, has been major driving factors in the expansion of the supplement industry. |
|
Key Trends |
Growing young population across the region, government directives to include fiber-rich foods in daily diets, and rising per-capita income are some of the factors driving Asia Pacific dietary fibres market growth. |
A unified Market Research Subscription Platform, built for today's disparate research needs.
Which Is The Leading Segment In The Obesity Management Market By Drug Type?
The liraglutide had the largest market share of 32.4%. Liraglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with a long pharmacokinetic profile that preserves biological activity.
These products promote weight loss by suppressing appetite and energy consumption. GLP-1 receptor agonists can also cause significant weight loss in a short period of time, which will drive growth in the coming decade.
Which Is The Leading Segment In The Obesity Management Market By Surgery Type?
Gastric sleeve surgery will remain dominant in the market during the forecast period, with an estimated 43.5% market share by the end of 2032. Gastric sleeve surgery is very convenient and safe, with excellent patient outcomes.
This procedure induces hormonal changes to aid in weight loss. These hormones not only help with weight loss, but also with high blood pressure and heart disease caused by obesity. It is the simplest methodology and requires less time in surgery.
Which Is The Leading Segment In The Obesity Management Market By Distribution Channel?
The hospital pharmacies will account for more than 50% of the global distribution channel. Elevated footfall in hospitals for anti-obesity counseling sessions contributes to a large share of market revenue.
Regional Outlook
North America
With a total market share of more than 63.0% in 2021, the United States is expected to maintain a high growth rate throughout the forecast period. Obesity is a major health issue in the country, resulting in a variety of diseases.
North America is expected to generate significant revenue in the obesity management market in the coming years. Factors like a high population awareness, the presence of prominent drug manufacturers, and the rising prevalence of obesity account for the region's rapid growth in the obesity management market.
The bupropion and naltrexone segment leads the North American obesity management market and is likely to sustain its lead, making it highly appealing to stakeholders.
Europe
Europe contributes significantly to the obesity management market's revenue. Obesity in the region is exacerbated by high intake of processed meats and a high prevalence of lifestyle diseases. The availability of obesity management health programmes and government-led obesity management health centres bodes well for the region's obesity management market growth.
Asia Pacific
Asia Pacific is rapidly emerging as a key market for obesity management. Obesity management programmes have emerged as a result of the region's developing countries' excessive rise in obesity incidence as a result of changing lifestyle. This fuels the regional obesity management market.
Propensity for Obesity Management Growth in India
India dominates the South Asian market with a market share of 60.9% and is expected to grow at a CAGR of 4.8%. Rising healthcare expenditures are expected to strengthen the country's market.
Obesity among adults is expected to triple between 2010 and 2040, with an estimated 30% of the population being overweight by that time. Obesity is increasing in the country due to increased consumption of energy-dense foods, sedentary lifestyle, a lack of health care services, and an inadequate financial support.
Germany's Key Growth Enabling Factors
Germany will hold 17.6% of the European obesity management market in 2021. The Robert Koch Institute reports that 67% of adults in Germany are overweight. Germany has a significant problem with high cholesterol and type 1 diabetes.
The German federal government is enacting policies to combat the country's growing obesity problem. In addition, the number of anti-obesity clinics in the country has increased. These factors will contribute to the expansion of obesity management in the country.
The Russian Obesity Management Market is Financially Viable
With a market value of US$ 36.6 Mn in 2021, Russia occupies an important financially rewarding position in Europe. Since 2014, the number of Russians diagnosed with obesity has increased by nearly 50%. According to the WHO, more than 60% of Russians are overweight, with 20% being obese.
The Russian Health Ministry is constantly striving to create strategies for enhancing the population's overall health. According to the World Factbook, the prevalence of adult obesity in Russia is 23.1%.
The Growth Potential in China's Obesity Management Market
The obesity management market in China is growing at a CAGR of 4.3% and is expected to account for more than 42% of the East Asian market over the forecast period. According to national survey data, more than half of all Chinese adults are now overweight or obese.
Rapid economic growth in the country in recent decades has resulted in significant changes in lifestyle, diet, and exercise habits. According to the National Health Commission report from 2020, more than half of adults are classified as overweight, with 16.4% being obese.
How Is The Start-Up Ecosystem In The Obesity Management Market?
Business models evolve over time, sometimes as a result of changes in the obesity management market, and sometimes as a result of technological advancements, resulting in the emergence of new and exciting obesity management market trends.
Standout Market Players You Should Know: Allurion Insights, Apollo Endosurgery, Inc., Obalon Therapeutics, and Glyscend Therapeutics
- Launch:
Allurion Insights, a new and powerful addition to the Allurion Virtual Care Suite, was launched today by Allurion Technologies, a pioneering leader in the development of innovative, scalable, and trusted weight loss experiences. Allurion Insights is a weight-loss provider-specific integrated remote patient monitoring and telehealth solution.
- Approval:
Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, announced that the US Food and Drug Administration (FDA) has approved the ORBERATM Intragastric Balloon to help adult patients with obesity (BMI 30 to 40) lose and maintain weight.
- Approval:
Obalon Therapeutics is making its stock market debut with a $75 million IPO to fund the commercialization of its weight loss balloon device in the United States. The product launch comes just a few weeks after Obalon filed for an IPO and revealed that its ingestible weight loss balloon had received FDA PMA approval.
- Financing Round
Glyscend Therapeutics has completed a $20.5 million Series A financing round. The round of funding was led by healthcare investors Brandon Capital Partners, through its Medical Research Commercialisation Fund (MRCF), and Santé Ventures, and will be used to support the development of the company's novel oral polymer therapy for patients with T2D and other metabolic diseases. In 2019, Breakout Labs provided seed funding.
How Competition Influences The Obesity Management Market?
The obesity management market is relatively consolidated, with only a few major players competing. Humongous players in the obesity management market are involved in R&D for product innovation and development of existing products.
GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. are among the prominent companies operating in the obesity management market.
Recent Development
| Date | January 2018 |
| Company Name | H2-Pharma |
| Strategy | Collaboration |
| Details | H2-Pharma announced collaboration with Cheplapharm Arzneimittel GmbH in January 2018 and re-launched XENICAL® 120 mg capsules through its newly formed branded division. |
| Date | February 2020 |
| Company Name | VIVUS, Inc. |
| Strategy | Collaboration |
| Details | VIVUS, Inc. announced in February 2020 that its Korean marketing partner, Alvogen, had launched Qsymia in the Republic of Korea. |
| Date | June 2021 |
| Company Name | Novo Nordisk |
| Strategy | FDA approval |
| Details | Novo Nordisk received FDA approval for Wegovy semaglutide injection in adults with at least one weight-related condition in June 2021. |
Key Players
- GlaxoSmithKline Plc.
- VIVUS, Inc.
- Novo Nordisk A/S
- Currax Pharmaceuticals LLC
- Cheplapharm Arzneimittel GmbH
- Bausch Health Companies Inc.
- Takeda Pharmaceuticals, Inc.
Key Segments
By Drug Type:
- Bupropion and Naltrexone
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
- Liraglutide
By Surgery Type:
- Gastric Bypass Surgery
- Adjustable Gastric Banding Surgery
- Gastric Sleeve Surgery
- Duodenal Switch Surgery
- Others
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
How is the Obesity Management Market Growing?
The Obesity Management Market is predicted to grow at 5.1% CAGR through 2032.
Which Region Holds the Highest Revenue Potential in the Obesity Management Market?
United States Obesity Management Market holds the highest revenue potential.
What is the Current Obesity Management Market Size?
The Obesity Management Market size is anticipated to be over USD 828.71 million in 2022.
What is the Future Scope of Growth for the Obesity Management Market?
The Obesity Management Market is expected to surpass USD 1362.80 million by 2032.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Method Innovation / Development Trends 4. Market Background 4.1. Macro-Economic Factors 4.1.1. Global GDP Growth Outlook 4.1.2. Global Healthcare Outlook 4.1.3. Per Capita Healthcare Expenditure Outlook 4.2. Forecast Factors - Relevance & Impact 4.2.1. Increasing Focus On Body Toning and Grooming Therapy 4.2.2. Rise in Incidence Rate of lifestyle diseases 4.2.3. Growing Adoption and Demand for Obesity Treatment 4.2.4. Product Launch 4.2.5. Increasing Spending On Healthcare Per Capita 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity Analysis 5. COVID19 Crisis Analysis 5.1. Current COVID19 Probable Future Impact 5.2. Current GDP Projection and Probable Impact 5.3. Current Economic Projection as compared to 2008 financial analysis 5.4. COVID19 and Impact Analysis 5.5. 2020 Market Scenario 5.6. Recovery Scenario - Short term, Midterm and Long Term Impact 6. Key Success Factor 6.1. Disease Epidemiology 6.2. Regulatory Scenario 6.3. Drug Pipeline Assessment 7. Global Market Value (US$ Mn) Analysis 2017–2020 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2017–2020 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market 2017–2020 and Forecast 2022-2032, By Drug Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) By Drug Type, 2017–2020 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032 8.3.1. Bupropion and Naltrexone 8.3.2. Orlistat 8.3.3. Lorcaserin 8.3.4. Phentermine and Topiramate 8.3.5. Liraglutide 8.4. Market Attractiveness Analysis By Drug Type 9. Global Market 2017–2020 and Forecast 2022-2032, By Surgery Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) By Surgery Type , 2017–2020 9.3. Current and Future Market Size (US$ Mn)) Analysis and Forecast By Surgery Type , 2022-2032 9.3.1. Gastric Bypass Surgery 9.3.2. Adjustable Gastric Banding Surgery 9.3.3. Gastric Sleeve Surgery 9.3.4. Duodenal Switch Surgery 9.3.5. Others 9.4. Market Attractiveness Analysis By Surgery Type 10. Global Market 2017–2020 and Forecast 2022-2032, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) By Distribution Channel , 2017–2020 10.3. Current and Future Market Size (US$ Mn)) Analysis and Forecast By Distribution Channel, 2022-2032 10.3.1. Hospitals Pharmacies 10.3.2. Retail Pharmacies 10.3.3. E-commerce 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market 2017–2020 and Forecast 2022-2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2020 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market 2017–2020 and Forecast 2022-2032 12.1. Introduction 12.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Drug Type 12.3.3. By Surgery Type 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Latin America Market 2017–2020 and Forecast 2022-2032 13.1. Introduction 13.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Rest of Latin America 13.3.2. By Drug Type 13.3.3. By Surgery Type 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Europe Market 2017–2020 and Forecast 2022-2032 14.1. Introduction 14.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. Russia 14.3.1.7. BENELUX 14.3.1.8. Poland 14.3.1.9. Nordic 14.3.1.10. Rest of Europe 14.3.2. By Drug Type 14.3.3. By Surgery Type 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. East Asia Market 2017–2020 and Forecast 2022-2032 15.1. Introduction 15.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Type 15.3.3. By Surgery Type 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Market 2017–2020 and Forecast 2022-2032 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Drug Type 16.3.3. By Surgery Type 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Oceania Market 2017–2020 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Type 17.3.3. By Surgery Type 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Market 2017–2020 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market Taxonomy, 2017–2020 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. South Africa 18.3.1.3. Rest of Middle East and Africa 18.3.2. By Drug Type 18.3.3. By Surgery Type 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Key Countries Market 2022 & 2032 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Market 19.2.1. By Drug Type 19.2.2. By Surgery Type 19.2.3. By Distribution Channel 19.3. Canada Market 19.3.1. By Drug Type 19.3.2. By Surgery Type 19.3.3. By Distribution Channel 19.4. Brazil Market 19.4.1. By Drug Type 19.4.2. By Surgery Type 19.4.3. By Distribution Channel 19.5. Mexico Market 19.5.1. By Drug Type 19.5.2. By Surgery Type 19.5.3. By Distribution Channel 19.6. U.K. Market 19.6.1. By Drug Type 19.6.2. By Surgery Type 19.6.3. By Distribution Channel 19.7. Germany Market 19.7.1. By Drug Type 19.7.2. By Surgery Type 19.7.3. By Distribution Channel 19.8. Italy Market 19.8.1. By Drug Type 19.8.2. By Surgery Type 19.8.3. By Distribution Channel 19.9. France Market 19.9.1. By Drug Type 19.9.2. By Surgery Type 19.9.3. By Distribution Channel 19.10. Spain Market 19.10.1. By Drug Type 19.10.2. By Surgery Type 19.10.3. By Distribution Channel 19.11. Russia Market 19.11.1. By Drug Type 19.11.2. By Surgery Type 19.11.3. By Distribution Channel 19.12. BENELUX Market 19.12.1. By Drug Type 19.12.2. By Surgery Type 19.12.3. By Distribution Channel 19.13. Poland Market 19.13.1. By Drug Type 19.13.2. By Surgery Type 19.13.3. By Distribution Channel 19.14. Nordic Market 19.14.1. By Drug Type 19.14.2. By Surgery Type 19.14.3. By Distribution Channel 19.15. China Market 19.15.1. By Drug Type 19.15.2. By Surgery Type 19.15.3. By Distribution Channel 19.16. Japan Market 19.16.1. By Drug Type 19.16.2. By Surgery Type 19.16.3. By Distribution Channel 19.17. South Korea Market 19.17.1. By Drug Type 19.17.2. By Surgery Type 19.17.3. By Distribution Channel 19.18. India Market 19.18.1. By Drug Type 19.18.2. By Surgery Type 19.18.3. By Distribution Channel 19.19. Thailand Market 19.19.1. By Drug Type 19.19.2. By Surgery Type 19.19.3. By Distribution Channel 19.20. Malaysia Market 19.20.1. By Drug Type 19.20.2. By Surgery Type 19.20.3. By Distribution Channel 19.21. Indonesia Market 19.21.1. By Drug Type 19.21.2. By Surgery Type 19.21.3. By Distribution Channel 19.22. Australia Market 19.22.1. By Drug Type 19.22.2. By Surgery Type 19.22.3. By Distribution Channel 19.23. New Zealand Market 19.23.1. By Drug Type 19.23.2. By Surgery Type 19.23.3. By Distribution Channel 19.24. GCC Countries Market 19.24.1. By Drug Type 19.24.2. By Surgery Type 19.24.3. By Distribution Channel 19.25. South Africa Market 19.25.1. By Drug Type 19.25.2. By Surgery Type 19.25.3. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. GlaxoSmithKline Plc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Strategy Overview 21.3.1.4.1. Marketing Strategy 21.3.1.4.2. Product Strategy 21.3.1.4.3. Channel Strategy 21.3.2. VIVUS, Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Strategy Overview 21.3.2.4.1. Marketing Strategy 21.3.2.4.2. Product Strategy 21.3.2.4.3. Channel Strategy 21.3.3. Novo Nordisk A/S 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Strategy Overview 21.3.3.4.1. Marketing Strategy 21.3.3.4.2. Product Strategy 21.3.3.4.3. Channel Strategy 21.3.4. Currax Pharmaceuticals LLC 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Strategy Overview 21.3.4.4.1. Marketing Strategy 21.3.4.4.2. Product Strategy 21.3.4.4.3. Channel Strategy 21.3.5. Cheplapharm Arzneimittel GmbH 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Strategy Overview 21.3.5.4.1. Marketing Strategy 21.3.5.4.2. Product Strategy 21.3.5.4.3. Channel Strategy 21.3.6. Bausch Health Companies Inc. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Strategy Overview 21.3.6.4.1. Marketing Strategy 21.3.6.4.2. Product Strategy 21.3.6.4.3. Channel Strategy 21.3.7. Takeda Pharmaceuticals, Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Strategy Overview 21.3.7.4.1. Marketing Strategy 21.3.7.4.2. Product Strategy 21.3.7.4.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Region Table 05: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 08: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 11: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 12: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 14: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 15: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 16: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 17: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 18: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 19: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 20: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 21: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 22: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 23: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 24: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 25: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 26: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 27: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 28: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel Table 29: Middle East & Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Country Table 30: Middle East & Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Drug Type Table 31: Middle East & Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Surgery Type Table 32: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value Analysis (US$ Mn), 2017-2020 Figure 02: Global Market Value Forecast (US$ Mn), 2022-2032 Figure 03: Global Market Absolute $ Opportunity, 2022 - 2032 Figure 04: Global Market Share Analysis (%), By Drug Type, 2022-2032 Figure 05: Global Market Y-o-Y Analysis (%), By Drug Type, 2022-2032 Figure 06: Global Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 07: Global Market Share Analysis (%), By Surgery Type, 2022-2032 Figure 08: Global Market Y-o-Y Analysis (%), By Surgery Type, 2022-2032 Figure 09: Global Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 10: Global Market Share Analysis (%), By Distribution Channel, 2022-2032 Figure 11: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2022-2032 Figure 12: Global Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 13: Global Market Share Analysis (%), By Region, 2022-2032 Figure 14: Global Market Y-o-Y Analysis (%), By Region, 2022-2032 Figure 15: Global Market Attractiveness Analysis by Region, 2022-2032 Figure 16: North America Market Value Share, By Drug Type (2022 E) Figure 17: North America Market Value Share, By Surgery Type (2022 E) Figure 18: North America Market Value Share, By Distribution Channel (2022 E) Figure 19: North America Market Value Share, By Country (2022 E) Figure 20: North America Market Value Analysis (US$ Mn), 2017-2020 Figure 21: North America Market Value Forecast (US$ Mn), 2022-2032 Figure 22: North America Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 23: North America Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 24: North America Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 25: North America Market Attractiveness Analysis by Country, 2022-2032 Figure 26: Latin America Market Value Share, By Drug Type (2022 E) Figure 27: Latin America Market Value Share, By Surgery Type (2022 E) Figure 28: Latin America Market Value Share, By Distribution Channel (2022 E) Figure 29: Latin America Market Value Share, By Country (2022 E) Figure 30: Latin America Market Value Analysis (US$ Mn), 2017-2020 Figure 31: Latin America Market Value Forecast (US$ Mn), 2022-2032 Figure 32: Latin America Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 33: Latin America Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 34: Latin America Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 35: Latin America Market Attractiveness Analysis by Country, 2022-2032 Figure 36: Europe Market Value Share, By Drug Type (2022 E) Figure 37: Europe Market Value Share, By Surgery Type (2022 E) Figure 38: Europe Market Value Share, By Country (2022 E) Figure 39: Europe Market Value Share, By Distribution Channel (2022 E) Figure 40: Europe Market Value Analysis (US$ Mn), 2017-2020 Figure 41: Europe Market Value Forecast (US$ Mn), 2022-2032 Figure 42: Europe Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 43: Europe Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 44: Europe Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 45: Europe Market Attractiveness Analysis by Country, 2022-2032 Figure 46: South Asia Market Value Share, By Drug Type (2022 E) Figure 47: South Asia Market Value Share, By Surgery Type (2022 E) Figure 48: South Asia Market Value Share, By Distribution Channel (2022 E) Figure 49: South Asia Market Value Share, By Country (2022 E) Figure 50: South Asia Market Value Analysis (US$ Mn), 2017-2020 Figure 51: South Asia Market Value Forecast (US$ Mn), 2022-2032 Figure 52: South Asia Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 53: South Asia Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 54: South Asia Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 55: South Asia Market Attractiveness Analysis by Country, 2022-2032 Figure 56: East Asia Market Value Share, By Drug Type (2022 E) Figure 57: East Asia Market Value Share, By Surgery Type (2022 E) Figure 58: East Asia Market Value Share, By Distribution Channel (2022 E) Figure 59: East Asia Market Value Share, By Country (2022 E) Figure 60: East Asia Market Value Analysis (US$ Mn), 2017-2020 Figure 61: East Asia Market Value Forecast (US$ Mn), 2022-2032 Figure 62: East Asia Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 63: East Asia Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 64: East Asia Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 65: East Asia Market Attractiveness Analysis by Country, 2022-2032 Figure 66: Oceania Market Value Share, By Drug Type (2022 E) Figure 67: Oceania Market Value Share, By Surgery Type (2022 E) Figure 68: Oceania Market Value Share, By Distribution Channel (2022 E) Figure 69: Oceania Market Value Share, By Country (2022 E) Figure 70: Oceania Market Value Analysis (US$ Mn), 2017-2020 Figure 71: Oceania Market Value Forecast (US$ Mn), 2022-2032 Figure 72: Oceania Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 73: Oceania Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 74: Oceania Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 75: Oceania Market Attractiveness Analysis by Country, 2022-2032 Figure 76: Middle East & Africa Market Value Share, By Drug Type (2022 E) Figure 77: Middle East & Africa Market Value Share, By Surgery Type (2022 E) Figure 78: Middle East & Africa Market Value Share, By Distribution Channel (2022 E) Figure 79: Middle East & Africa Market Value Share, By Country (2022 E) Figure 80: Middle East & Africa Market Value Analysis (US$ Mn), 2017-2020 Figure 81: Middle East & Africa Market Value Forecast (US$ Mn), 2022-2032 Figure 82: Middle East & Africa Market Attractiveness Analysis by Drug Type, 2022-2032 Figure 83: Middle East & Africa Market Attractiveness Analysis By Surgery Type, 2022-2032 Figure 84: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 85: Middle East & Africa Market Attractiveness Analysis by Country, 2022-2032 Figure 86: U.S. Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 87: U.S. Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 88: U.S. Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 89: Global Vs. U.S. Growth Comparison Figure 90: Canada Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 91: Canada Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 92: Canada Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 93: Global Vs. Canada Growth Comparison Figure 94: Brazil Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 95: Brazil Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 96: Brazil Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 97: Global Vs. Brazil Growth Comparison Figure 98: Mexico Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 99: Mexico Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 100: Mexico Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 101: Global Vs. Mexico Growth Comparison Figure 102: U.K Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 103: U.K Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 104: U.K. Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 105: Global Vs. U.K Growth Comparison Figure 106: Germany Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 107: Germany Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 108: Germany Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 109: Global Vs. Germany Growth Comparison Figure 110: Italy Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 111: Italy Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 112: Italy Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 113: Global Vs. Italy Growth Comparison Figure 114: France Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 115: France Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 116: France Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 117: Global Vs. France Growth Comparison Figure 118: Spain Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 119: Spain Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 120: Spain Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 121: Global Vs. Spain Growth Comparison Figure 122: Russia Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 123: Russia Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 124: Russia Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 125: Global Vs. Russia Growth Comparison Figure 126: BENELUX Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 127: BENELUX Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 128: BENELUX Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 129: Global Vs. BENELUX Growth Comparison Figure 130: Poland Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 131: Poland Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 132: Poland Australia Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 133: Global Vs. Poland Growth Comparison Figure 134: Nordic Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 135: Nordic Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 136: Nordic Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 137: Global Vs. Nordic Growth Comparison Figure 138: China Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 139: China Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 140: China Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 141: Global Vs. China Growth Comparison Figure 142: Japan Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 143: Japan Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 144: Japan Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 145: Global Vs. Japan Growth Comparison Figure 146: South Korea Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 147: South Korea Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 148: South Korea Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 149: Global Vs. South Korea Growth Comparison Figure 150: India Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 151: India Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 152: India Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 153: Global Vs. India Growth Comparison Figure 154: Thailand Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 155: Thailand Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 156: Thailand Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 157: Global Vs. Thailand Growth Comparison Figure 158: Malaysia Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 159: Malaysia Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 160: Malaysia Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 161: Global Vs. Malaysia Growth Comparison Figure 162: Indonesia Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 163: Indonesia Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 164: Indonesia Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 165: Global Vs. Indonesia Growth Comparison Figure 166: Australia Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 167: Australia Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 168: Australia Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 169: Global Vs. Australia Growth Comparison Figure 170: New Zealand Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 171: New Zealand Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 172: New Zealand Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 173: Global Vs. New Zealand Growth Comparison Figure 174: GCC Countries Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 175: GCC Countries Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 176: GCC Countries Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 177: Global Vs. GCC Countries Growth Comparison Figure 178: South Africa Market Share Analysis (%), By Drug Type, 2022 & 2032 Figure 179: South Africa Market Share Analysis (%), By Surgery Type, 2022 & 2032 Figure 180: South Africa Market Share Analysis (%), By Distribution Channel, 2022 &2032 Figure 181: Global Vs. South Africa Growth Comparison
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
